Share Article
- Fourth Quarter Product Sales of
- Full Year 2015 Product Sales of
- Full Year 2015 Non-GAAP EPS of
Full year 2015 total revenues were
| Three Months Ended | Twelve Months Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| (In millions, except per share amounts) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Product sales | $ | 8,409 | $ | 7,222 | $ | 32,151 | $ | 24,474 | ||||
| Royalty, contract and other revenues | 97 | 92 | 488 | 416 | ||||||||
| Total revenues | $ | 8,506 | $ | 7,314 | $ | 32,639 | $ | 24,890 | ||||
| Net income attributable to Gilead | $ | 4,683 | $ | 3,487 | $ | 18,108 | $ | 12,101 | ||||
| Non-GAAP net income attributable to Gilead | $ | 4,889 | $ | 3,883 | $ | 19,174 | $ | 13,314 | ||||
| Diluted EPS | $ | 3.18 | $ | 2.18 | $ | 11.91 | $ | 7.35 | ||||
| Non-GAAP diluted EPS | $ | 3.32 | $ | 2.43 | $ | 12.61 | $ | 8.09 | ||||
Product Sales
Total product sales for the fourth quarter of 2015 were
Total product sales during 2015 were
Antiviral Product Sales
Antiviral product sales, which include products in our HIV and liver
diseases areas, were
Other Product Sales
Other product sales, which include Letairis®, Ranexa®
and AmBisome®, were
Operating Expenses
| Three Months Ended | Twelve Months Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| (In millions) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Non-GAAP research and development expenses (R&D) | $ | 779 | $ | 899 | $ | 2,845 | $ | 2,585 | ||||
| Non-GAAP selling, general and administrative expenses (SG&A) | $ | 1,013 | $ | 799 | $ | 3,224 | $ | 2,757 | ||||
Note: Non-GAAP R&D and SG&A expenses exclude amounts related to acquisition, stock-based compensation and other.
________________________________
-
During the fourth quarter of 2015, non-GAAP R&D expenses decreased,
compared to same period in 2014, primarily due to the 2014 impact of
up-front fees paid in connection with Gilead's collaboration with
ONO Pharmaceutical Co., Ltd. (ONO) and the purchase of aU.S. Food and Drug Administration (FDA ) priority review voucher, partially offset by increased costs to support the continued progression of Gilead's clinical studies in 2015. -
During 2015, non-GAAP R&D expenses increased, compared to 2014,
primarily due to the progression of Gilead's clinical studies,
partially offset by the 2014 impact of up-front fees paid in
connection with Gilead's collaboration with ONO and the purchase of a
FDA priority review voucher. - During the fourth quarter and full year 2015, non-GAAP SG&A expenses increased, compared to same periods in 2014, primarily to support Gilead's growth and the geographic expansion of its business.
Cash,
As of
Full Year 2016 Guidance
Gilead provided its full year 2016 guidance:
| (In millions, except percentages and per share amounts) | Provided February 2, 2016 | ||
| Net Product Sales | $30,000 - $31,000 | ||
| Non-GAAP* | |||
| Product Gross Margin | 88% - 90% | ||
| R&D expenses | $3,200 - $3,500 | ||
| SG&A expenses | $3,300 - $3,600 | ||
| Effective Tax Rate | 18.0% - 20.0% | ||
| Diluted EPS Impact Related to Acquisition, Stock-Based Compensation and Other | $1.10 - $1.16 | ||
* Non-GAAP product gross margin, R&D and SG&A expenses and effective tax rate exclude amounts related to acquisition, stock-based compensation and other.
Corporate Highlights
-
Gilead was the top corporate HIV/AIDS philanthropic funder and the No.
2 private HIV/AIDS philanthropic funder overall behind the
Bill & Melinda Gates Foundation , according to the Funders Concerned About AIDS Report issued onDecember 8, 2015 . Gilead gave$73.4 million in HIV/AIDS philanthropic support in 2014. The company's corporate giving helps address the HIV epidemic on all fronts, including testing and linkage to care, enabling access to medicines, reducing disparities in the quality of healthcare and educating healthcare professionals on the latest advances in HIV therapies. -
Gilead is partnering with the U.S. government, the
Bill & Melinda Gates Foundation and other corporate donors on the DREAMS initiative aimed at reducing HIV infections among adolescent girls and young women in sub-Saharan Africa. Gilead will provide funding to help the program purchase generic Truvada for use as pre-exposure prophylaxis (PrEP) among HIV-negative adolescent girls and young women in sub-Saharan Africa, as well as to support costs related to procurement, transportation and dissemination of PrEP.
Product & Pipeline Updates Announced by
Antiviral Program
-
Announced that the
European Commission granted marketing authorization for the once-daily single tablet regimen Genvoya® for the treatment of HIV-1 infection. Genvoya is the first tenofovir alafenamide (TAF)-based regimen to receive marketing authorization in theEuropean Union (EU). Genvoya is indicated in the EU for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with HIV-1 without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. -
Announced that
FDA approved Genvoya for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receiveFDA approval. Genvoya is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA levels less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya. -
Announced positive 96-week results from two Phase 3 studies evaluating
Genvoya for the treatment of HIV-1 infection in treatment-naïve
adults. Genvoya was found to be statistically non-inferior to Stribild®,
based on percentages of patients with HIV-1 RNA levels less than 50
copies/mL. Patients receiving Genvoya also had improved renal and bone
laboratory parameters compared to those treated with Stribild. These
data were presented at the 15th
European AIDS Conference . -
Announced that the Marketing Authorization Application for an
investigational, once-daily fixed-dose combination of the nucleotide
analog polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir
(VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the
treatment of chronic hepatitis C virus (HCV) infection, was fully
validated and under assessment by the
European Medicines Agency (EMA). The data included in the application support the use of SOF/VEL among patients with genotype 1-6 HCV infection, including patients with compensated and decompensated cirrhosis. SOF/VEL is the third investigational medicinal product from Gilead for HCV infection to receive accelerated review by the EMA. -
Announced that
FDA approved Harvoni for expanded use in patients with genotype 4, 5 and 6 HCV infection and in patients co-infected with HIV. In addition, Harvoni plus ribavirin (RBV) for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment-experienced, genotype 1 patients with cirrhosis. -
Announced that the company submitted a New Drug Application to
FDA for an investigational, once-daily fixed-dose combination of SOF/VEL, for the treatment of chronic genotype 1-6 HCV infection. The NDA is supported by clinical studies exploring the use of 12 weeks of SOF/VEL for patients with genotype 1-6 HCV infection, including patients with compensated cirrhosis and 12 weeks of SOF/VEL with RBV for patients with decompensated cirrhosis.FDA assigned SOF/VEL with a Breakthrough Therapy designation, which is granted to investigational medicines that may offer major advances in treatment over existing options. -
Announced that the company fulfilled a request for compassionate
access to GS-5734, a novel nucleotide analogue in development for the
potential treatment of Ebola Virus Disease. The compound was provided
to two patients, one a female patient in the
Royal Free Hospital inLondon in October and one inGuinea the following month, through a compassionate use request. Two Phase 1 human trials are now underway in healthy adult volunteers.
Oncology Program
-
Announced positive results from a prespecified interim analysis of a
Phase 3 study evaluating Zydelig® in combination with
bendamustine and rituximab (BR) for patients with previously treated
chronic lymphocytic leukemia. The analysis found a 67 percent
reduction in the risk of disease progression or death
(progression-free survival) in patients receiving Zydelig plus BR
compared to BR alone. Additionally, all secondary endpoints, including
overall survival, achieved statistical significance in this interim
analysis. These data were presented at the Annual Meeting of the
American Society of Hematology .
Cardiovascular Program
-
Announced that
FDA approved the use of Letairis in combination with tadalafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Inflammation Program
-
Announced that Gilead and
Galapagos NV entered into a collaboration for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory disease indications. This collaboration represents an opportunity to add complementary clinical programs to our growing inflammation research and development efforts. Phase 2 trial data show that filgotinib has the potential to be an effective and well-tolerated oral therapy for patients with rheumatoid arthritis (RA) and Crohn’s disease. Phase 3 trials in RA and Crohn’s are expected to start in mid-2016 pending the successful outcome of discussions with regulatory authorities.
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. GAAP (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8 and 9.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2016 financial results; Gilead's ability to
sustain growth in revenues for its antiviral and other programs;
availability of funding for state AIDS Drug Assistance Programs (ADAPs);
continued fluctuations in ADAP purchases driven by federal and state
grant cycles which may not mirror patient demand and may cause
fluctuations in Gilead's earnings; the possibility of unfavorable
results from clinical trials involving investigational compounds,
including GS-5734 and filgotinib; Gilead's ability to initiate clinical
trials in its currently anticipated timeframes; the levels of inventory
held by wholesalers and retailers which may cause fluctuations in
Gilead's earnings; Gilead's ability to submit new drug applications for
new product candidates in the timelines currently anticipated; Gilead's
ability to receive regulatory approvals in a timely manner or at all,
for new and current products, including F/TAF, R/F/TAF and SOF/VEL;
Gilead's ability to successfully commercialize its products, including
Genvoya; the risk that physicians and patients may not see advantages of
these products over other therapies and may therefore be reluctant to
prescribe the products; the risk that estimates of patients with HCV or
anticipated patient demand may not be accurate; the risk that private
and public payers may be reluctant to provide, or continue to provide,
coverage or reimbursement for new products, including Sovaldi and
Harvoni; Gilead's ability to successfully develop its oncology,
inflammation, cardiovascular and respiratory programs; safety and
efficacy data from clinical studies may not warrant further development
of Gilead's product candidates; the potential for pricing pressure from
additional competitive HCV launches or austerity measures in European
countries and
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 8,409 | $ | 7,222 | $ | 32,151 | $ | 24,474 | ||||||||
| Royalty, contract and other revenues | 97 | 92 | 488 | 416 | ||||||||||||
| Total revenues | 8,506 | 7,314 | 32,639 | 24,890 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 1,062 | 1,063 | 4,006 | 3,788 | ||||||||||||
| Research and development expenses | 757 | 1,045 | 3,014 | 2,854 | ||||||||||||
| Selling, general and administrative expenses | 1,066 | 876 | 3,426 | 2,983 | ||||||||||||
| Total costs and expenses | 2,885 | 2,984 | 10,446 | 9,625 | ||||||||||||
| Income from operations | 5,621 | 4,330 | 22,193 | 15,265 | ||||||||||||
| Interest expense | (230 | ) | (130 | ) | (688 | ) | (412 | ) | ||||||||
| Other income (expense), net | 46 | 30 | 154 | 3 | ||||||||||||
| Income before provision for income taxes | 5,437 | 4,230 | 21,659 | 14,856 | ||||||||||||
| Provision for income taxes | 752 | 768 | 3,553 | 2,797 | ||||||||||||
| Net income | 4,685 | 3,462 | 18,106 | 12,059 | ||||||||||||
| Net income (loss) attributable to noncontrolling interest | 2 | (25 | ) | (2 | ) | (42 | ) | |||||||||
| Net income attributable to Gilead | $ | 4,683 | $ | 3,487 | $ | 18,108 | $ | 12,101 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 3.26 | $ | 2.32 | $ | 12.37 | $ | 7.95 | ||||||||
| Shares used in per share calculation - basic | 1,436 | 1,506 | 1,464 | 1,522 | ||||||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 3.18 | $ | 2.18 | $ | 11.91 | $ | 7.35 | ||||||||
| Shares used in per share calculation - diluted | 1,472 | 1,597 | 1,521 | 1,647 | ||||||||||||
| Cash dividends declared per share | $ | 0.43 | $ | — | $ | 1.29 | $ | — | ||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 1,062 | $ | 1,063 | $ | 4,006 | $ | 3,788 | ||||||||
| Acquisition related-amortization of purchased intangibles | (206 | ) | (218 | ) | (826 | ) | (818 | ) | ||||||||
| Stock-based compensation expenses | (2 | ) | (2 | ) | (11 | ) | (10 | ) | ||||||||
| Other (1) | 3 | 4 | 6 | 4 | ||||||||||||
| Non-GAAP cost of goods sold | $ | 857 | $ | 847 | $ | 3,175 | $ | 2,964 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 87.4 | % | 85.3 | % | 87.5 | % | 84.5 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.4 | % | 3.0 | % | 2.6 | % | 3.3 | % | ||||||||
| Other (1) | — | % | 0.1 | % | — | % | — | % | ||||||||
| Non-GAAP product gross margin(2) | 89.8 | % | 88.3 | % | 90.1 | % | 87.9 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 757 | $ | 1,045 | $ | 3,014 | $ | 2,854 | ||||||||
| Acquisition related expenses | — | (85 | ) | (66 | ) | (85 | ) | |||||||||
| Stock-based compensation expenses | (45 | ) | (41 | ) | (173 | ) | (152 | ) | ||||||||
| Other (1) | 67 | (20 | ) | 70 | (32 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 779 | $ | 899 | $ | 2,845 | $ | 2,585 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 1,066 | $ | 876 | $ | 3,426 | $ | 2,983 | ||||||||
| Acquisition related-amortization of purchased intangibles | — | (15 | ) | — | (18 | ) | ||||||||||
| Stock-based compensation expenses | (50 | ) | (52 | ) | (198 | ) | (198 | ) | ||||||||
| Other (1) | (3 | ) | (10 | ) | (4 | ) | (10 | ) | ||||||||
| Non-GAAP selling, general and administrative expenses | $ | 1,013 | $ | 799 | $ | 3,224 | $ | 2,757 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 66.1 | % | 59.2 | % | 68.0 | % | 61.3 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.4 | % | 3.2 | % | 2.5 | % | 3.4 | % | ||||||||
| Acquisition related expenses | — | % | 1.2 | % | 0.2 | % | 0.3 | % | ||||||||
| Stock-based compensation expenses | 1.1 | % | 1.3 | % | 1.2 | % | 1.4 | % | ||||||||
| Other (1) | (0.8 | )% | 0.4 | % | (0.2 | )% | 0.1 | % | ||||||||
| Non-GAAP operating margin(2) | 68.9 | % | 65.2 | % | 71.7 | % | 66.6 | % | ||||||||
| Other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | 46 | $ | 30 | $ | 154 | $ | 3 | ||||||||
| Other (1) | — | — | 1 | (2 | ) | |||||||||||
| Non-GAAP other income (expense), net | $ | 46 | $ | 30 | $ | 155 | $ | 1 | ||||||||
| (1) Amounts related to consolidation of a contract manufacturer, contingent consideration and/or other individually insignificant amounts | ||||||||||||||||
(2) Amounts may not sum due to rounding | ||||||||||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 13.8 | % | 18.2 | % | 16.4 | % | 18.8 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | — | % | (0.8 | )% | (0.3 | )% | (0.9 | )% | ||||||||
| Stock-based compensation expenses | — | % | — | % | 0.1 | % | — | % | ||||||||
| Other (1) | 0.1 | % | (0.1 | )% | — | % | — | % | ||||||||
| Non-GAAP effective tax rate(2) | 13.9 | % | 17.3 | % | 16.2 | % | 17.9 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 4,683 | $ | 3,487 | $ | 18,108 | $ | 12,101 | ||||||||
| Acquisition related-amortization of purchased intangibles | 203 | 226 | 808 | 815 | ||||||||||||
| Acquisition related expenses | — | 71 | 66 | 71 | ||||||||||||
| Stock-based compensation expenses | 67 | 79 | 251 | 296 | ||||||||||||
| Other (1) | (64 | ) | 20 | (59 | ) | 31 | ||||||||||
| Non-GAAP net income attributable to Gilead | $ | 4,889 | $ | 3,883 | $ | 19,174 | $ | 13,314 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 3.18 | $ | 2.18 | $ | 11.91 | $ | 7.35 | ||||||||
| Acquisition related-amortization of purchased intangibles | 0.14 | 0.14 | 0.53 | 0.49 | ||||||||||||
| Acquisition related expenses | — | 0.04 | 0.04 | 0.04 | ||||||||||||
| Stock-based compensation expenses | 0.05 | 0.05 | 0.17 | 0.18 | ||||||||||||
| Other (1) | (0.04 | ) | 0.01 | (0.04 | ) | 0.02 | ||||||||||
| Non-GAAP diluted earnings per share (2) | $ | 3.32 | $ | 2.43 | $ | 12.61 | $ | 8.09 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,472 | 1,597 | 1,521 | 1,647 | ||||||||||||
| Share impact of current stock-based compensation rules | — | (1 | ) | — | (1 | ) | ||||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,472 | 1,596 | 1,521 | 1,646 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 205 | $ | 216 | $ | 831 | $ | 824 | ||||||||
| Research and development expenses adjustments | (22 | ) | 146 | 169 | 269 | |||||||||||
| Selling, general and administrative expenses adjustments | 53 | 77 | 202 | 226 | ||||||||||||
| Other income (expense) adjustments | — | — | 1 | (2 | ) | |||||||||||
| Total non-GAAP adjustments before tax | 236 | 439 | 1,203 | 1,317 | ||||||||||||
| Income tax effect | (34 | ) | (38 | ) | (150 | ) | (99 | ) | ||||||||
| Other (1) | 4 | (5 | ) | 13 | (5 | ) | ||||||||||
| Total non-GAAP adjustments after tax attributable to Gilead | $ | 206 | $ | 396 | $ | 1,066 | $ | 1,213 | ||||||||
| (1) Amounts related to consolidation of a contract manufacturer, contingent consideration and/or other individually insignificant amounts | ||||||||||||||||
| (2) Amounts may not sum due to rounding | ||||||||||||||||
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) | |||||||
| December 31, | December 31, | ||||||
| 2015 | 2014 (1) | ||||||
| Cash, cash equivalents and marketable securities | $ | 26,208 | $ | 11,726 | |||
| Accounts receivable, net | 5,854 | 4,635 | |||||
| Inventories | 1,955 | 1,386 | |||||
| Property, plant and equipment, net | 2,276 | 1,674 | |||||
| Intangible assets, net | 10,247 | 11,073 | |||||
| Goodwill | 1,172 | 1,172 | |||||
| Other assets | 4,127 | 2,998 | |||||
| Total assets | $ | 51,839 | $ | 34,664 | |||
| Current liabilities | $ | 9,891 | $ | 5,761 | |||
| Long-term liabilities | 22,833 | 13,069 | |||||
| Equity component of redeemable convertible notes | 2 | 15 | |||||
| Stockholders’ equity(2) | 19,113 | 15,819 | |||||
| Total liabilities and stockholders’ equity | $ | 51,839 | $ | 34,664 | |||
(1) Derived from the audited consolidated financial statements as of December 31, 2014. | |||||||
(2) As of December 31, 2015, there were 1,422 shares of common stock issued and outstanding. | |||||||
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) | |||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2015 | 2014 | 2015 | 2014 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Harvoni – U.S. | $ | 1,707 | $ | 2,001 | $ | 10,090 | $ | 2,001 | |||||||
| Harvoni – Europe | 587 | 83 | 2,219 | 103 | |||||||||||
| Harvoni – Other International | 1,051 | 23 | 1,555 | 23 | |||||||||||
| 3,345 | 2,107 | 13,864 | 2,127 | ||||||||||||
| Sovaldi – U.S. | 660 | 1,178 | 2,388 | 8,507 | |||||||||||
| Sovaldi – Europe | 259 | 459 | 1,601 | 1,546 | |||||||||||
| Sovaldi – Other International | 628 | 95 | 1,287 | 230 | |||||||||||
| 1,547 | 1,732 | 5,276 | 10,283 | ||||||||||||
| Truvada – U.S. | 587 | 548 | 2,057 | 1,787 | |||||||||||
| Truvada – Europe | 272 | 287 | 1,118 | 1,275 | |||||||||||
| Truvada – Other International | 77 | 62 | 284 | 278 | |||||||||||
| 936 | 897 | 3,459 | 3,340 | ||||||||||||
| Atripla – U.S. | 582 | 668 | 2,222 | 2,357 | |||||||||||
| Atripla – Europe | 161 | 194 | 694 | 888 | |||||||||||
| Atripla – Other International | 57 | 63 | 218 | 225 | |||||||||||
| 800 | 925 | 3,134 | 3,470 | ||||||||||||
| Stribild – U.S. | 408 | 319 | 1,476 | 1,014 | |||||||||||
| Stribild – Europe | 83 | 52 | 282 | 145 | |||||||||||
| Stribild – Other International | 20 | 14 | 67 | 38 | |||||||||||
| 511 | 385 | 1,825 | 1,197 | ||||||||||||
| Complera / Eviplera – U.S. | 216 | 196 | 796 | 663 | |||||||||||
| Complera / Eviplera – Europe | 149 | 138 | 576 | 513 | |||||||||||
| Complera / Eviplera – Other International | 15 | 14 | 55 | 52 | |||||||||||
| 380 | 348 | 1,427 | 1,228 | ||||||||||||
| Viread – U.S. | 156 | 164 | 541 | 484 | |||||||||||
| Viread – Europe | 77 | 77 | 310 | 336 | |||||||||||
| Viread – Other International | 73 | 70 | 257 | 238 | |||||||||||
| 306 | 311 | 1,108 | 1,058 | ||||||||||||
| Genvoya – U.S. | 44 | — | 44 | — | |||||||||||
| Genvoya – Europe | 1 | — | 1 | — | |||||||||||
| Genvoya – Other International | — | — | — | — | |||||||||||
| 45 | — | 45 | — | ||||||||||||
| Other Antiviral – U.S. | 9 | 12 | 39 | 46 | |||||||||||
| Other Antiviral – Europe | 6 | 7 | 26 | 35 | |||||||||||
| Other Antiviral – Other International | 1 | 2 | 4 | 7 | |||||||||||
| 16 | 21 | 69 | 88 | ||||||||||||
| Total antiviral products – U.S. | 4,369 | 5,086 | 19,653 | 16,859 | |||||||||||
| Total antiviral products – Europe | 1,595 | 1,297 | 6,827 | 4,841 | |||||||||||
| Total antiviral products – Other International | 1,922 | 343 | 3,727 | 1,091 | |||||||||||
| 7,886 | 6,726 | 30,207 | 22,791 | ||||||||||||
| Other products: | |||||||||||||||
| Letairis | 192 | 181 | 700 | 595 | |||||||||||
| Ranexa | 169 | 144 | 588 | 510 | |||||||||||
| AmBisome | 74 | 104 | 350 | 388 | |||||||||||
| Zydelig | 40 | 17 | 132 | 23 | |||||||||||
| Other | 48 | 50 | 174 | 167 | |||||||||||
| 523 | 496 | 1,944 | 1,683 | ||||||||||||
| Total product sales | $ | 8,409 | $ | 7,222 | $ | 32,151 | $ | 24,474 | |||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20160202006542/en/
Source:
Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Patrick O'Brien, 650-522-1936MediaAmy Flood, 650-522-5643
Other News
Some of the content on this page is not intended for users outside the U.S.